NEW YORK (GenomeWeb News) – WaferGen Biosystems said today that researchers at the University of Pittsburgh working under a grant from the National Institutes of Health will use the company’s PCR system in gene expression studies of lung disease.
Using a grant of around $3 million from the National Heart, Lung, and Blood Institute, the Pittsburgh scientists will use WaferGen’s SmartChip Real-Time PCR System to apply gene expression profiling to lung samples from patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
The research program also will include development and application of the PulmoSmartChip, a custom-designed SmartChip phenotyping assay for COPD and IPF that will identify and validate module networks that can help predict the natural history of the disease and the patient’s response.
The aim of the study is to identify and validate gene expression signatures and microenvironments, while generating module maps that can be used to characterize COPD and IPF and their underlying causes.
Financial terms of the agreement between WaferGen and the university were not disclosed.